Advanced Filters
noise

One or multiple investigational sites, Spain Clinical Trials

A listing of One or multiple investigational sites, Spain clinical trials actively recruiting patients volunteers.

Found 64,772 clinical trials

Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects

A clinical trial to investigate the safety and tolerability of single and multiple intranasal (through the nose) dosing with the study drug CHF6467 in 68 healthy adult subjects. The study will investigate also how CHF6467 moves and behaves in the blood and in the fluid around the brain and spinal …

18 - 55 years of age All Phase 1

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).

18 years of age Female Phase 2/3
Y Yuqin Song, Doctor

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

18 - 80 years of age All Phase 2
L Liangshan Wang, MD

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

18 years of age All Phase N/A
L Linnea Bärebring

Effects of Meal Characteristics on Appetite

The overall aim of the study is to determine effects of different meal characteristics on energy intake, eating rate and appetite.

18 - 64 years of age All Phase N/A
G Guldana Abdullaeva, MD

A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:

The purpose of this study is to evaluate the bioavailability, safety and tolerability of Torasemide 10 mg tablets (Berlin-Chemie AG), compared to Unat® 10 tablets (Viatris Healthcare GmbH) in healthy adult participants under fasting conditions.

18 - 55 years of age All Phase 1
P Peng Liu

Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System

The study is to evaluate the accuracy and safety of a novel real-time continuous glucose and ketone monitoring system among adult patients with type 1 diabetes mellitus (T1DM) with respect to Yellow Spring Instrument (YSI) and Randox reference venous plasma sample measurements.

18 years of age All Phase N/A
W Wenbo Zhao, M.D.

Urokinase for Thrombolysis in Acute Ischemic Stroke

According to the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke, intravenous thrombolysis with urokinase, administered at doses of 1-1.5 million IU within 6 hours of symptom onset, has been shown to be both safe and effective for patients with acute ischemic stroke. Compared to alteplase, urokinase offers …

18 - 80 years of age All Phase N/A
M Martin Wermke, MD

Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific combination mutated KRAS and HLA, activating the T cells and exerting anti- tumour activity in patients with …

18 years of age All Phase 1/2
S Sarada Radha

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

18 - 65 years of age All Phase 1

Simplify language using AI